Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.47 |
| ▸ | RPTOR | Q8N122 | 9/20 | 0.43 |
| ▸ | MLST8 | Q9BVC4 | 9/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828915 | 1.00 | MTOR (0.47) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL29829235 | 0.84 | MTOR (0.47) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL2339312 | 0.84 | MTOR (0.47) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL29829856 | 0.82 | MTOR (0.46) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL2334350 | 0.82 | MTOR (0.46) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL2334709 | 0.81 | MTOR (0.44) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL29828884 | 0.81 | MTOR (0.44) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL29522486 | 0.78 | MTOR (0.76) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL137259 | 0.78 | MTOR (0.76) | MTORPIK3CARPTORMLST8SYK | |
| SCHEMBL27882288 | 0.74 | SYK (0.41) | MTORPIK3CARPTORMLST8SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20180235960-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9937170-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9557338-B2 | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9375443-B2 | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160008356-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150362505-A1 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARM LLC (US) | 2015-12-17 | — | — | US | disclosed |
| US-9155736-B2 | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140113905-A1 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130225518-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008356-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, CHEK1, TNK1 | MTOR 1/4885PIK3CA 47/4885RPTOR 49/4885 |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885PIK3CA 9/4885RPTOR 6/4885 |
| US-20180235960-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885PIK3CA 9/4885RPTOR 6/4885 |
| US-20130225518-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | DCK, DTYMK, MTOR | MTOR 3/4885PIK3CA 14/4885RPTOR 48/4885 |
| US-20140113905-A1 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | MTOR, GSK3B, RPS6KA4 | MTOR 1/4885PIK3CA 32/4885RPTOR 9/4885 |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | MTOR, TTK, RICTOR | MTOR 1/4885PIK3CA 9/4885RPTOR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.